for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boston Scientific Corporation

BSX.N

Latest Trade

43.40USD

Change

0.15(+0.35%)

Volume

1,967,122

Today's Range

43.06

 - 

43.68

52 Week Range

32.99

 - 

46.28

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Boston Scientific Announces Positive Late-Breaking Clinical Trial Data For The Ranger Drug-Coated Balloon

Oct 5 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES POSITIVE LATE-BREAKING CLINICAL TRIAL DATA FOR THE RANGER™ DRUG-COATED BALLOON.BOSTON SCIENTIFIC - TWO-YEAR DATA DEMONSTRATE CONTINUED HIGH RATES OF PRIMARY PATENCY INCLUDING IN PATIENTS WITH COMPLEX LESIONS.BOSTON SCIENTIFIC - RANGER DCB, WHICH HAS LOW DRUG DOSE DENSITY OF PACLITAXEL, ALSO DEMONSTRATED SIGNIFICANT REDUCTION IN REINTERVENTIONS AT TWO YEARS.

Minerva Surgical Inc Files For IPO Of Up To $100 Million

Sept 27 (Reuters) - Boston Scientific Corp <BSX.N>::MINERVA SURGICAL INC FILES FOR IPO OF UP TO $100 MILLION.MINERVA SURGICAL INC SAYS APPLIED TO LIST ITS COMMON STOCK ON NASDAQ UNDER SYMBOL "UTRS".MINERVA SURGICAL INC SAYS BOSTON SCIENTIFIC CORP OWNS 6% OF ITS SHARES OF COMMON STOCK PRIOR TO IPO.MINERVA SURGICAL INC SAYS J.P. MORGAN, PIPER SANDLER, UBS INVESTMENT BANK, SVB LEERINK ARE AMONG UNDERWRITERS TO THE IPO.MINERVA SURGICAL INC SAYS PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.

Boston Scientific Agrees To Acquire Devoro Medical

Sept 21 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES AGREEMENT TO ACQUIRE DEVORO MEDICAL, INC..BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF AN UPFRONT PAYMENT OF APPROXIMATELY $269 MILLION FOR 84 PERCENT STAKE NOT YET OWNED.BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF PAYMENT OF UP TO $67 MILLION UPON ACHIEVEMENT OF CERTAIN CLINICAL AND REGULATORY MILESTONES.BOSTON SCIENTIFIC CORP - ON AN ADJUSTED BASIS, TRANSACTION IS EXPECTED TO BE SLIGHTLY DILUTIVE TO EARNINGS PER SHARE (EPS) IN 2021.BOSTON SCIENTIFIC CORP - IN 2022, DEAL IS NOT EXPECTED TO IMPACT ADJUSTED EPS AND WILL BE SLIGHTLY DILUTIVE ON A GAAP BASIS.

FDA Says Boston Scientific Recalls Ingenio Family Of Pacemakers And Crt-Ps Due To Risk Of Transition To Safety Mode

Aug 10 (Reuters) - FDA::FDA SAYS BOSTON SCIENTIFIC RECALLS INGENIO FAMILY OF PACEMAKERS AND CRT-PS DUE TO RISK OF TRANSITION TO SAFETY MODE.FDA SAYS BOSTON SCIENTIFIC'S RECALL OF INGENIO FAMILY OF PACEMAKERS AND CRT-PS IDENTIFIED AS A CLASS I RECALL.FDA SAYS THERE HAVE BEEN 65 REPORTED INCIDENTS, INCLUDING THREE INJURIES WHICH REQUIRED PATIENTS TO RECEIVE TEMPORARY EXTERNAL PACING.Further company coverage: BSX.N. ((Reuters.Briefs@thomsonreuters.com;)).

FDA Says Boston Scientific Recalling Ingenio Family Of Pacemakers And CRT-Ps

Aug 6 (Reuters) - U.S. FDA: :FDA - BOSTON SCIENTIFIC IS RECALLING INGENIO FAMILY OF PACEMAKERS AND CRT-PS DUE TO THE RISK OF INCORRECT TRANSITION TO SAFETY MODE.FDA - HAS IDENTIFIED RECALL OF INGENIO FAMILY OF PACEMAKERS AND CRT-PS AS A CLASS I RECALL.FDA - THERE HAVE BEEN 65 REPORTED INCIDENTS, INCLUDING 3 INJURIES WHICH REQUIRED PATIENTS TO RECEIVE TEMPORARY EXTERNAL PACING.Further company coverage: BSX.N. ((Reuters.Briefs@thomsonreuters.com;)).

Boston Scientific Reports Q2 Earnings Per Share $0.12

July 27 (Reuters) - Boston Scientific Corp <BSX.N>::SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 19% TO 20% ON ORGANIC BASIS (ADDS SOURCE).BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR SECOND QUARTER 2021.Q2 GAAP EARNINGS PER SHARE $0.12.Q2 SALES $3.077 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.94 BILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.37 -- REFINITIV IBES DATA.Q2 ADJUSTED EARNINGS PER SHARE $0.40.QTRLY CARDIOVASCULAR SEGMENT SALES $1,263 MILLION VERSUS $834 MILLION REPORTED LAST YEAR.SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 21%-22% ON A REPORTED BASIS.BOSTON SCIENTIFIC-SEES Q3 EPS ON A GAAP BASIS IN A RANGE OF $0.20 TO $0.22 AND ADJUSTED EPS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $0.39 TO $0.41.BOSTON SCIENTIFIC - CO SEES NET SALES GROWTH FOR FY 2021 TO BE IN RANGE OF 21-22 PERCENT ON A REPORTED BASIS & 19 - 20 PERCENT ON AN ORGANIC BASIS.SEES NET SALES GROWTH FOR Q3 TO BE ABOUT 12% TO 14% ON BOTH A REPORTED AND ORGANIC BASIS.SEES 2021 ESTIMATES EPS ON A GAAP BASIS OF $0.79-$0.83, ADJUSTED EPS EXCLUDING CERTAIN CHARGES (CREDITS) OF $1.58-$1.62.FY2021 EARNINGS PER SHARE VIEW $1.58, REVENUE VIEW $11.75 BILLION -- REFINITIV IBES DATA.Q3 EARNINGS PER SHARE VIEW $0.40, REVENUE VIEW $2.97 BILLION -- REFINITIV IBES DATA.Further company coverage: <BSX.N>. ((Reuters.Briefs@thomsonreuters.com;)).

Boston Scientific Exercises Option To Acquire Farapulse Inc

June 24 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC CORP - EXERCISED ITS OPTION TO ACQUIRE REMAINING SHARES OF FARAPULSE INC.BOSTON SCIENTIFIC CORP - TRANSACTION CONSISTS OF AN UPFRONT PAYMENT OF APPROXIMATELY $295 MILLION FOR 73 PERCENT STAKE NOT YET OWNED.BOSTON SCIENTIFIC CORP - ON AN ADJUSTED BASIS, TRANSACTION IS EXPECTED TO BE SLIGHTLY DILUTIVE TO ADJUSTED EPS IN 2021 AND 2022.BOSTON SCIENTIFIC CORP - ON A GAAP BASIS, TRANSACTION IS EXPECTED TO BE MORE DILUTIVE DILUTIVE TO ADJUSTED EARNINGS PER SHARE (EPS) IN 2021 AND 2022.

FDA Says Boston Scientific Recalls VICI VENOUS STENT System And VICI RDS VENOUS STENT System

May 21 (Reuters) - U.S FDA: :FDA - BOSTON SCIENTIFIC CORPORATION RECALLS VICI VENOUS STENT SYSTEM AND VICI RDS VENOUS STENT SYSTEM FOR POTENTIAL OF STENT MIGRATION.FDA - IDENTIFIED RECALL OF BOSTON SCIENTIFIC'S VICI VENOUS STENT SYSTEM AND VICI RDS VENOUS STENT SYSTEM AS A CLASS I RECALL.

Boston Scientific Corp Says On May 10, Entered Into $2.750 Billion Revolving Credit Agreement

May 13 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC CORP - ON MAY 10, ENTERED INTO $2.750 BILLION REVOLVING CREDIT AGREEMENT.BOSTON SCIENTIFIC CORP - 2021 REVOLVING CREDIT AGREEMENT MATURES ON MAY 10, 2026, WITH ONE-YEAR EXTENSION OPTIONS SUBJECT TO CERTAIN CONDITIONS.

Boston Scientific Announces Results For First Quarter 2021

April 28 (Reuters) - Boston Scientific Corp <BSX.N>::BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2021.Q1 GAAP EARNINGS PER SHARE $0.23.Q1 SALES $2.752 BILLION.Q1 ADJUSTED EARNINGS PER SHARE $0.37.NOW SEES NET SALES GROWTH FOR 2021 TO BE ABOUT 16%-19% ON A REPORTED BASIS, AND ABOUT 15%-18% ON AN ORGANIC BASIS.NOW ESTIMATES 2021 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.81 TO $0.88 PER SHARE.ESTIMATES 2021 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $1.53 TO $1.60 PER SHARE.QTRLY CARDIOVASCULAR SEGMENTS SALES $1,129 MILLION VERSUS $1,026 MILLION.FY2021 EARNINGS PER SHARE VIEW $1.54, REVENUE VIEW $11.43 BILLION -- REFINITIV IBES DATA.Q1 EARNINGS PER SHARE VIEW $0.31, REVENUE VIEW $2.62 BILLION -- REFINITIV IBES DATA.CO ESTIMATES NET SALES GROWTH FOR Q2 OF 2021, TO BE IN A RANGE OF ABOUT 46 TO 50 PERCENT ON A REPORTED BASIS.NOW ESTIMATES Q2 EARNINGS ON A GAAP BASIS IN A RANGE OF $0.16 TO $0.18 PER SHARE.NOW ESTIMATES Q2 ADJUSTED EARNINGS, EXCLUDING CERTAIN CHARGES (CREDITS), OF $0.36 TO $0.38 PER SHARE.Q2 EARNINGS PER SHARE VIEW $0.35 -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up